Trastuzumab and pertuzumab

trastuzumab  Trastuzumab is a biologic antineoplastic agent that, at the time of its FDA approval in 1998, was among the first available targeted chemotherapies  Cardiotoxicity Trastuzumab is a monoclonal antibody tyrosine kinase inhibitor that targets the HER2 receptor often over overexpressed or overactive in breast

Trastuzumab deruxtecan Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal trastuzumab Early breast cancer Herceptin is indicated for the treatment of patients with HER2-positive early breast cancer: following surgery

trastuzumab beyond progression Trastuzumab is generally well tolerated and does not cause many of the toxicities or side effects seen with conventional (จากประโยชน์ของยา trastuzumab ทำให้การตรวจ HER2 ถือเป็นมาตรฐานของการตรวจชิ้นเนื้อมะเร็งเต้านมควบคู่กับก ารตรวจ hormone receptor โดยถือว่ามะเร็งเต้านมนั้นมี